标题: Agenix to develop the Institute of Medicinal Biotechnology's AGX-1009(anti-HBV) [打印本页] 作者: interdetect 时间: 2011-4-5 21:48 标题: Agenix to develop the Institute of Medicinal Biotechnology's AGX-1009(anti-HBV)
Agenix, under license from the Institute of Medicinal Biotechnology (IMB) of the Chinese Academy of Medical
Sciences, is investigating prodrug analog AGX-1009, a nucleotide analog reverse transcriptase inhibitor
(NtRTI), for the potential treatment of hepatitis B virus (HBV) infection.
In September 2010, Agenix reported that AGX-1009 did not inhibit cytochrome P450 at doses above therapeutic
levels.
By September 2010, it was reported that from preliminary pharmacodynamic, pharmacokinetic and toxicity
studies performed by IMB researchers, AGX-1009 had demonstrated inhibition against HIV-1 and HBV, as well
as a low toxicity profile and high oral bioavailability. 作者: StephenW 时间: 2011-4-5 22:15
